Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Xavier Quantin
Neoadjuvant Pembrolizumab Associated with Chemotherapy in Early Breast Cancer Patients: Real-World Data from a French Single-Center Experience
Submitted: 06 December 2025 You are already at the latest version Introduction The addition of immunotherapy to neoadjuvant treatment for early triple-negative breast cancer (TNBC) has been adopted in clinical practice in France since March 2022 with little real-world data published on the topic. The aim of this study was to evaluate real world data on treatment feasibility, efficacy and related toxicities, with a specific focus on immune-related adverse events (irAEs).
Artificial intelligence-driven microsatellite instability profiling reveals distinctive genetic features in patients with lung cancer
INTRODUCTION Lung cancer is the main cause of cancer-related death worldwide.1 Non–small cell lung cancer (NSCLC) is the most frequent histological type (80%–85%) and is frequently diagnosed at an advanced or metastatic stage.2 Immunotherapy using immune checkpoint-blocking antibodies (ICIs) targeting programmed death-1 or its ligand (PD-1/PD-L1) has improved outcomes in patients with early-stage, locally advanced, and metastatic NSCLC.3-6 PD-L1 expression in tumor cells (tumor proportion...
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicenter cohort
1 M, 49; melanoma, lymph node No Combo ipilimumab + nivolumab 20 Vitiligo, thyroiditis Cholestatic, grade 3 ANA 1/320, ASMA negative 6.84 interface hepatitis, eosinophilia, fibrin ring granulomas Steroids 1.5 mg/kg, UDCA 500 mg Mycophenolate mofetil, 92 136 2 F, 54; melanoma, lymph node No Pembrolizumab 220 No Cholestatic, grade 3 ANA negative, ASMA negative 4.33 interface hepatitis, eosinophilia, mixed cholangitis ∗ Mixed cholangitis, lymphocytic cholangitis and non-suppurative destructive...
Highlights • Grade 3/4 and fatal imAEs were uncommon with durvalumab after CRT. • Pneumonitis and thyroid disorders were the most common imAEs with this regimen. • ImAEs typically occurred within 3 months of durvalumab initiation. • In general, imAEs were well managed with appropriate clinical intervention. • Time elapsed between RT and randomization did not impact imAE incidence or severity.
Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO’s adverse drug reactions database
Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis?
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial
Armelle Lavole, Laurent Greillier, Julien Mazières, Isabelle Monnet, Lize Kiakouama-Maleka, Xavier Quantin, Jean Philippe Spano, Herve Lena, Philippe Fraisse, Henri Janicot, Clarisse Audigier-Valette, Alexandra Langlais, Franck Morin, Alain Makinson, Jacques Cadranel on behalf of the French Cooperative Thoracic Intergroup (IFCT) European Respiratory Journal 2020 56: 1902066; DOI: 10.1183/13993003.02066-2019 Abstract HIV infection is an exclusion criterion in lung cancer trials.
Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO’s adverse drug reactions database
Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis?
Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis?An analysis of the WHO’s adverse drug reactions database
Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis?An analysis of the WHO’s adverse drug reactions database Free Thủy Nguyễn1, http://orcid.org/0000-0002-0868-5804Alexandre Thibault Jacques Maria2,3, Chayma Ladhari1, Pascale Palassin1, Xavier Quantin4, Candice Lesage5, Guillaume Taïeb6, Xavier Ayrignac6, Patricia Rullier2, Dominique Hillaire-Buys1, Olivier Lambotte7, Philippe Guilpain2,3, Jean-Luc Faillie1 1Department of Medical Pharmacology and Toxicology,...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Xavier
Contact Xavier, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack